Echocardiography for the diagnosis of CTRCD in women with early-stage breast cancer
JAMA — Esmaeilzadeh M, Fresno CMU, Somerset E, et al. | February 11, 2022
In clinical practice, timely diagnosis of cancer therapy–related cardiac dysfunction (CTRCD) could be improved via combined use of echocardiography 3-dimensional (3-D) left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and global circumferential strain (GCS).
Researchers assessed the correctness of an algorithm employing echocardiography and serum biomarkers for the timely diagnosis of CTRCD defined using cardiovascular magnetic resonance (CMR).
In this cohort study, a total of 136 women (mean [SD] age, 51.1 [9.2] years) with human epidermal growth factor receptor 2–positive early-stage breast cancer were included.
Exposures included sequential therapy with anthracyclines and trastuzumab.
Good discriminatory accuracy for concurrent CMR-detected CTRCD was achieved with a combined approach of using echocardiographic 3-D LVEF, GLS, and GCS, but not by high-sensitivity troponin I and B-type natriuretic.
The likelihood of CTRCD as defined by CMR was 1.0% when none of the 3-D LVEF, GLS, and GCS CTRCD criteria were met.
Read the full article on JAMA